Study Phase 3

A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.

Trial Information

Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment215% FemaleN/A% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-CHN-T100Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)N/A

Supporting Documentation

  • Protocol with Amendments Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol and full clinical study report are available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.